Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

January 20, 2026

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

January 12, 2026

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

January 11, 2026

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Teva Pharmaceutical Industries Ltd

Royalty Pharma Announces Dividend Increase

January 09, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Topics Artificial Intelligence Intellectual Property

3 Overrated Stocks We Steer Clear Of

December 31, 2025

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

December 29, 2025

Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over...

3 Healthcare Stocks We’re Skeptical Of

December 16, 2025

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

Topics Stocks

December 16, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

What's going on in today's after hours session ↗

December 08, 2025

Via Chartmill

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗

December 06, 2025

Royalty Pharma (RPRX) shows a strong technical breakout setup with a perfect 10/10 trend score and a 9/10 formation score, signaling a potential upward move.

Via Chartmill

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

December 04, 2025

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

December 04, 2025

From Denali Therapeutics Inc.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

3 Mid-Cap Stocks That Concern Us

December 03, 2025

Royalty Pharma to Present at Upcoming Investor Conferences

November 26, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Via Investor's Business Daily

3 Value Stocks with Warning Signs

November 17, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Topics Supply Chain

3 Low-Volatility Stocks We Find Risky

November 16, 2025

Royalty Pharma trades at $39.59 and has moved in lockstep with the market. Its shares have returned 20.6% over the last six months while the S&P 500 has gained 16.4%.

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

November 12, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Topics Stocks Supply Chain

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

Topics Intellectual Property

Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗

November 05, 2025

Royalty Pharma's Q3 2025 earnings beat estimates, with strong revenue and EPS. The company also raised its full-year 2025 guidance.

Via Chartmill

Topics Earnings

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

Royalty Pharma Reports Third Quarter 2025 Results

November 05, 2025

Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences

November 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2

November 03, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before the bell. Here’s what to look for.

Topics Artificial Intelligence Intellectual Property

What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings

November 03, 2025